• Novo Nordisk A/S, of Bagsvaerd, Denmark, said its ultra-long-lasting insulin degludec significantly reduced the rate of hypoglycemia at night in adults with Type II diabetes, while obtaining equivalent improvement in glucose control compared with insulin glargine over a 52-week period. Data from that Phase IIIa trial were presented at the American Diabetes Association meeting in Philadelphia.